Relmada Therapeutics (RLMD) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
27 May, 2026Opening remarks and agenda
The meeting was called to order at 9:30 A.M. with a quorum of 63.5% voting power present.
Stockholders were welcomed and informed of the opportunity for Q&A after the formal meeting.
Board and executive committee updates
Charles J. Casamento and Sergio Traversa were nominated for election as Class II directors for a three-year term.
Shareholder proposals
Four proposals were presented: election of directors, ratification of auditors, amendment to the equity incentive plan, and amendment to the articles of incorporation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Relmada Therapeutics
- NDV-01 demonstrates high efficacy in NMIBC, with Phase 3 trials and strong financial runway ahead.RLMD
Corporate presentation11 Jun 2026 - NDV-01 advances to phase III with strong data, broadening access and maintaining solid financials.RLMDJefferies Global Healthcare Conference 20264 Jun 2026
- NDV-01 shows robust efficacy and $160M financing secures Phase 3 launch and long-term runway.RLMDQ1 202619 May 2026
- NDV-01 demonstrates high efficacy in NMIBC, with robust financials supporting late-stage trials.RLMDCorporate presentation12 May 2026
- NDV-01 demonstrates high response rates in NMIBC, with pivotal trials and strong financial backing ahead.RLMDCompany presentation12 May 2026
- NDV-01 delivers strong efficacy and safety in bladder cancer, with pivotal trials and funding secured.RLMDLeerink Global Healthcare Conference 202630 Apr 2026
- A strategic pivot and successful financing in 2025 set the stage for renewed growth and shareholder value.RLMDProxy filing17 Apr 2026
- Key votes include director elections, equity plan expansion, and increasing authorized shares.RLMDProxy filing17 Apr 2026
- Shareholders will vote on key governance, compensation, and capital structure changes after a pivotal turnaround.RLMDProxy filing6 Apr 2026